The 2026 Antimicrobial Resistance Threats Report from the CDC categorizes 19 bacterial and fungal pathogens by level of threat to health in the US.
|Videos|September 22, 2017
What Makes ABSSSI Antibiotic Iclaprim Unique?
Author(s)Contagion® Editorial Staff
William D. O’Riordan, MD, FACEP, explains what makes iclaprim a unique antibiotic.
Advertisement
William D. O’Riordan, MD, FACEP, chief medical officer, eStudySite, explains how iclaprim has a unique mechanism of action, making it a unique antibiotic to treat acute bacterial skin and skin structure infections. Dr. O’Riordan explains how dihydrofolate reductase interferes with an enzyme that is involved with the bacterial cell and essentially “does away” with it.
Advertisement
Related to this article
A CDC analysis of Antimicrobial Resistance Laboratory Network data found pediatric carbapenemase-producing CRE incidence in the United States rose 92% from 2019 to 2024, driven mostly by NDM-producing organisms.
Here is a case that was linked to a unique travel history and led to a series of acute health issues.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Recent urinary tract infection guideline updates from multiple international
medical societies highlight evolving recommendations, including a major shift
in classification, moving from anatomy- and risk factor–based definitions
toward distinguishing localized from systemic infections.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Advertisement
Advertisement
Trending on Contagion Live
1
Ebola Update: DRC Outbreak Tops 10,000 Cases as Kenya, Nigeria Report Spread
2
Is the mRNA Influenza Vaccine More Efficacious in Older Adults?
3
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
4
CDC Updates Report on Antimicrobial Resistance
5